Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -16,755 | -18,546 | -17,565 | -6,843 | -2,344 |
| Depreciation Amortization | 535 | 517 | 99 | 43 | N/A |
| Other Working Capital | -352 | -1,082 | 1,309 | 432 | 310 |
| Other Operating Activity | 3,236 | 1,037 | 395 | 1,102 | 1,541 |
| Operating Cash Flow | $-13,336 | $-18,075 | $-15,763 | $-5,267 | $-493 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -22 | -36 | -101 | -252 | N/A |
| Investing Cash Flow | $-22 | $-36 | $-101 | $-252 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 1,190 |
| Common Stock Issued | 16,401 | 15,909 | 6 | 26,335 | N/A |
| Other Financing Activity | 0 | 0 | 0 | -819 | -74 |
| Financing Cash Flow | $16,401 | $15,909 | $6 | $25,517 | $1,117 |
| Beginning Cash Position | 2,768 | 4,968 | 20,826 | 828 | 205 |
| End Cash Position | 5,811 | 2,768 | 4,968 | 20,826 | 828 |
| Net Cash Flow | $3,044 | $-2,201 | $-15,857 | $19,998 | $624 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,336 | -18,075 | -15,763 | -5,267 | -493 |
| Capital Expenditure | -22 | -36 | -101 | -255 | N/A |
| Free Cash Flow | -13,358 | -18,110 | -15,863 | -5,522 | -493 |